What's breaking now, across thousands of outlets.
Vorzeitig bekannt gewordene Studiendaten zu einem Krebsimpfstoff setzen Moderna und Merck & Co. unter Druck. Die Moderna-Aktie verliert zeitweise 26 Prozent.
We haven't written up this one. Handelsblatt has the full story — the link below goes straight to it.
Public confidence in the CDC and FDA has fallen to record lows, with just 26% and 25% of Americans, respectively, rating the agencies’ performance as excellent or good in a Gallup poll.
The three organizations—Redesign Health, ARC Global and AVIA—work with more than 100 health systems on five continents, and the companies and products built across their networks have reached more…
The uninsured rate has climbed over the past two years as Medicaid work requirements—which are expected to drive their own coverage losses—loom at the beginning of 2027.
New data on a closely watched Lyme disease vaccine from Pfizer and Valneva provide details on the near-miss in one of two analyses, as the vaccine's commercial future hangs in the balance.
Moderna shares plunged as much as 25% after partial clinical trial data leaked for its personalized cancer vaccine developed with Merck, despite the full results showing promising outcomes for…
The WHO said it was working with French authorities to establish the source of the infection, possible routes of transmission and any potential public health risks The post France reports first human…
